Company Filing History:
Years Active: 2009-2013
Title: Albert Collinson: Innovator in Dual Specificity Antibodies
Introduction
Albert Collinson is a notable inventor based in Marlboro, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of dual specificity antibodies. With a total of 2 patents, his work has the potential to impact therapeutic approaches for various disorders.
Latest Patents
Collinson's latest patents focus on dual specificity antibodies and methods of making and using them. These antibodies are designed to have dual specificity for two different but structurally related antigens, such as IL-1α and IL-1β. The antibodies can be entirely human, recombinant, or monoclonal. They are capable of neutralizing IL-1α and IL-1β activity both in vitro and in vivo. The invention includes methods for making and using these antibodies, which are useful for detecting and inhibiting the activity of the antigens in human subjects suffering from related disorders.
Career Highlights
Throughout his career, Collinson has worked with prominent companies in the biotechnology sector, including Abbott Laboratories Corporation and AbbVie Inc. His experience in these organizations has contributed to his expertise in antibody development and therapeutic applications.
Collaborations
Some of Collinson's notable coworkers include George Avgerinos and Richard W. Dixon. Their collaboration has likely fostered innovative ideas and advancements in the field of biotechnology.
Conclusion
Albert Collinson's work in dual specificity antibodies represents a significant advancement in medical science. His contributions have the potential to lead to new therapeutic strategies for managing disorders related to IL-1 activity.